乙酰水杨酸所致胃肠道损伤的最新研究进展综述:机制、药物治疗及剂量优化
Review on recent advancements in understanding acetylsalicylic acid-induced gastrointestinal injury: mechanisms, medication, and dosage refinement.
作者信息
Zhou Jiahui, Li Na, Li Xinzhong, Ye Jingxue, Wang Min, Sun Guibo
机构信息
Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100193, China.
出版信息
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):3297-3320. doi: 10.1007/s00210-024-03521-w. Epub 2024 Nov 15.
Acetylsalicylic acid (ASA) is a clinical drug with multiple effects, including prevention of cardiovascular adverse events and anti-cancer effects. However, gastrointestinal side effects, such as gastrointestinal ulcers and bleeding, limit the use of ASA and reduce patient compliance. Various studies have investigated the mechanisms of ASA-induced gastrointestinal injury, and many medicines have been reported to be effective in preventing and treating the adverse gastrointestinal effects of ASA. New formulations of ASA have demonstrated milder gastrointestinal injury than ASA alone. In this article, we summarized the mechanisms of ASA-induced gastrointestinal injury, drugs that resist gastrointestinal side effects of ASA, and progress in research on formulation improvement of ASA to help resolve the clinical dilemma of ASA usage.
乙酰水杨酸(ASA)是一种具有多种作用的临床药物,包括预防心血管不良事件和抗癌作用。然而,胃肠道副作用,如胃溃疡和出血,限制了ASA的使用并降低了患者的依从性。各种研究已经探究了ASA诱导胃肠道损伤的机制,并且据报道许多药物在预防和治疗ASA的胃肠道不良反应方面是有效的。ASA的新制剂已显示出比单独使用ASA时更轻的胃肠道损伤。在本文中,我们总结了ASA诱导胃肠道损伤的机制、抵抗ASA胃肠道副作用的药物以及ASA制剂改进的研究进展,以帮助解决ASA使用的临床困境。